<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Platelets contain several factors that inhibit <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>This study was designed to assess the <z:chebi fb="5" ids="28304">heparin</z:chebi>-neutralizing activity present in <z:hpo ids='HP_0011009'>acute</z:hpo>, platelet-rich arterial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> formed at sites of arterial injury in animals </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Platelet-rich <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> (n = 3) were induced in pig coronary arteries by balloon catheter-mediated arterial injury </plain></SENT>
<SENT sid="3" pm="."><plain>Soluble extracts were prepared from each <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> and assayed for the capacity to inhibit <z:chebi fb="5" ids="28304">heparin</z:chebi> in an in vitro clotting assay (activated partial thromboplastin time) </plain></SENT>
<SENT sid="4" pm="."><plain>Mean <z:chebi fb="5" ids="28304">heparin</z:chebi>-neutralizing activity was 28 U of <z:chebi fb="5" ids="28304">heparin</z:chebi> neutralized per milliliter of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e>, indicating that 1 vol of coronary <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> completely inhibited the <z:chebi fb="5" ids="28304">heparin</z:chebi> present in 140 vols of therapeutically anticoagulated (0.2 U <z:chebi fb="5" ids="28304">heparin</z:chebi>/mL) plasma </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> extracts had no effect on the <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity of hirudin, a direct-acting thrombin inhibitor </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:chebi fb="5" ids="28304">heparin</z:chebi>-neutralizing activity present in coronary <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> bound to <z:chebi fb="5" ids="28304">heparin</z:chebi>-<z:chebi fb="2" ids="2511">agarose</z:chebi> and was eluted from it by 1.4 mol/L <z:chebi fb="1" ids="26710">NaCl</z:chebi>, suggesting that platelet factor 4 mediated the antiheparin effect of <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Consistent with this hypothesis, a murine monoclonal antibody to rabbit platelet factor 4 nearly completely inhibited the <z:chebi fb="5" ids="28304">heparin</z:chebi>-neutralizing activity present in rabbit <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> (n = 3) generated by carotid artery injury </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Extracts prepared from platelet-rich arterial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> significantly inhibit the in vitro <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> potency of <z:chebi fb="5" ids="28304">heparin</z:chebi> but not of hirudin </plain></SENT>
<SENT sid="9" pm="."><plain>This antiheparin effect appears to be mediated by platelet factor 4 </plain></SENT>
<SENT sid="10" pm="."><plain>These results are consistent with the hypothesis that localized inhibition of <z:chebi fb="5" ids="28304">heparin</z:chebi> at sites of platelet activation may reduce its antithrombotic efficacy </plain></SENT>
<SENT sid="11" pm="."><plain>In addition, they suggest an additional mechanism for the apparent superiority of hirudin over <z:chebi fb="5" ids="28304">heparin</z:chebi> as a thrombin inhibitor at sites of arterial injury </plain></SENT>
</text></document>